登录 | 注册    关注公众号  
搜索
 > 【RON】

RON信息

英文名称:Macrophage-stimulating protein receptor
中文名称:巨噬细胞刺激蛋白受体
靶点别称:EC 2.7.10.1,Protein-Tyrosine Kinase 8,RON,Macrophage-Stimulating Protein Receptor,SEA,S13 Erythroblastosis Oncogene Homolog,S13 Erythroblastosis (Avian) Oncogene Homolog,Macrophage Stimulating 1 Receptor,PTK8 Protein Tyrosine Kinase 8,S13 Avian Erythroblastosis Oncogene Homolog,MST1R,NPCA3,CD136 Antigen,C-Met-Related Tyrosine Kinase,CD136,CDw136,PTK8,P185-Ron,EC:2.7.10.1,MSP Receptor,EC 2.7.10
上市药物数量:1
临床药物数量:5
最高研发阶段:批准上市

RON产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
RON-H52H9
Human
Human RON / MSPR Protein, His Tag
 
评论(0)
 

RON 分子别名

CD136 antigen,CD136,CDw136c-met-related tyrosine kinase,EC 2.7.10,EC 2.7.10.1,macrophage stimulating 1 receptor (c-met-related tyrosine kinase),MSP R,MSP receptor,MSPR,MST1R,p185-Ron,Protein-tyrosine kinase 8,PTK8 protein tyrosine kinase 8,PTK8,Ron,RONmac

RON 分子背景

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

RON 前沿进展

RON上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Crizotinib 克唑替尼 PF-1066; PF-2341066; PF-02341066; PF-002341066 批准上市 辉瑞制药有限公司 赛可瑞, Xalkori United States 间变大细胞淋巴瘤 Pf Prism Cv 2011-08-26 结直肠癌, 转移癌, 神经鞘瘤, 腺癌, 非小细胞肺癌, 子宫内膜癌, 间变大细胞淋巴瘤, 非霍奇金淋巴瘤, 鳞状细胞癌, 肺癌, 输尿管肿瘤, 实体瘤, 尿道癌, 神经母细胞瘤, 葡萄膜黑色素瘤, 膀胱癌, 肌纤维瘤, 多发性骨髓瘤, 肾脏疾病, 神经纤维瘤病II型, 肿瘤, 血液肿瘤 详情

RON临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Narnatumab 礼来制药 详情
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Mirati Therapeutics 详情
Ningetinib Tosylate CT-053-PTSA; CT-053 临床一期 宜昌东阳光药业股份有限公司 肠道肿瘤, 胃癌, 肾细胞癌, 肺癌, 急性髓细胞样白血病, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定